These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15073687)

  • 1. No evidence of an association between transient HIV viremia ("Blips") and lower adherence to the antiretroviral medication regimen.
    Miller LG; Golin CE; Liu H; Hays RD; Hua J; Wenger NS; Kaplan AH
    J Infect Dis; 2004 Apr; 189(8):1487-96. PubMed ID: 15073687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia.
    Podsadecki TJ; Vrijens BC; Tousset EP; Rode RA; Hanna GJ
    J Infect Dis; 2007 Dec; 196(12):1773-8. PubMed ID: 18190257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy.
    Macias J; Palomares JC; Mira JA; Torres MJ; García-García JA; Rodríquez JM; Vergera S; Pineda JA
    J Infect; 2005 Oct; 51(3):195-200. PubMed ID: 16230215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance.
    Masquelier B; Pereira E; Peytavin G; Descamps D; Reynes J; Verdon R; Fleury H; Garraffo R; Chêne G; Raffi F; Brun-Vézinet F;
    J Clin Virol; 2005 May; 33(1):75-8. PubMed ID: 15797369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
    Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG
    Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy.
    Di Mascio M; Ribeiro RM; Markowitz M; Ho DD; Perelson AS
    Math Biosci; 2004; 188():47-62. PubMed ID: 14766093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between cellular human immunodeficiency virus DNA level and immunological parameters in patients with undetectable plasma viremia level during highly active antiretroviral therapy.
    Sarmati L; Parisi SG; Nicastri E; d'Ettorre G; Palmisano L; Andreotti M; Andreoni C; Giuliano M; Gatti F; Boldrin C; Palù G; Vullo V; Vella S; Andreoni M
    J Clin Microbiol; 2005 Dec; 43(12):6183-5. PubMed ID: 16333125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection and quantification of proviral HIV-1 184 M/V in circulating CD4(+) T cells of patients on HAART with a viremia less than 1,000 copies/ml.
    Mohey R; Jørgensen LB; Møller BK; Black FT; Kjems J; Obel N
    J Clin Virol; 2005 Dec; 34(4):257-67. PubMed ID: 16286049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.
    Mocroft A; Phillips AN; Ledergerber B; Katlama C; Chiesi A; Goebel FD; Knysz B; Antunes F; Reiss P; Lundgren JD
    AIDS; 2006 May; 20(8):1141-50. PubMed ID: 16691065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duration of an intermittent episode of viremia.
    Di Mascio M; Percus JK; Percus OE; Markowitz M; Ho DD; Perelson AS
    Bull Math Biol; 2005 Jul; 67(4):885-900. PubMed ID: 15893558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A programmable prompting device improves adherence to highly active antiretroviral therapy in HIV-infected subjects with memory impairment.
    Andrade AS; McGruder HF; Wu AW; Celano SA; Skolasky RL; Selnes OA; Huang IC; McArthur JC
    Clin Infect Dis; 2005 Sep; 41(6):875-82. PubMed ID: 16107989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV.
    Grossberg R; Zhang Y; Gross R
    J Clin Epidemiol; 2004 Oct; 57(10):1107-10. PubMed ID: 15528063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The correlation between plasma concentrations of protease inhibitors, medication adherence and virological outcome in HIV-infected patients.
    Yasuda JM; Miller C; Currier JS; Forthal DN; Kemper CA; Beall GN; Tilles JG; Capparelli EV; McCutchan JA; Haubrich RH;
    Antivir Ther; 2004 Oct; 9(5):753-61. PubMed ID: 15535413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Undetectable viremia without antiretroviral therapy in patients with HIV seroconversion: an uncommon phenomenon?
    Madec Y; Boufassa F; Rouzioux C; Delfraissy JF; Meyer L;
    Clin Infect Dis; 2005 May; 40(9):1350-4. PubMed ID: 15825038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significant link between sCD30 changes and HIV viremia in patients treated with HAART.
    Biswas P; Cozzi-Lepri A; Delfanti F; Galli A; Colangeli V; Moioli MC; Scarchilli A; Abrescia N; Vigevani G; D'Arminio-Monforte A; Novati R; Lazzarin A
    J Med Virol; 2006 Dec; 78(12):1513-9. PubMed ID: 17063513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors.
    Maggiolo F; Ravasio L; Ripamonti D; Gregis G; Quinzan G; Arici C; Airoldi M; Suter F
    Clin Infect Dis; 2005 Jan; 40(1):158-63. PubMed ID: 15614706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.